Doxycycline: An essential tool for Alzheimer's disease

Area of Science:

• Neurology
• Pharmacology
• Biochemistry

Background:

• Identifying effective treatments for neurodegenerative disorders remains a significant challenge.
• Repurposed drugs offer a promising strategy for developing new therapeutic interventions.
• Tetracyclines, including doxycycline, possess structural properties that interfere with amyloid formation.

Purpose of the Study:

• To investigate the potential of doxycycline as a therapeutic agent for neurodegenerative diseases.
• To evaluate the anti-amyloidogenic, anti-prion, anti-inflammatory, and antioxidant properties of doxycycline.
• To explore the application of precision medicine principles in doxycycline treatment.

Main Methods:

• In vitro and in vivo experiments to assess anti-prion activity.
• Clinical trials in human subjects with prion-related encephalopathies.
• Studies on the interaction of doxycycline with amyloid-beta, alpha-synuclein, and tau aggregates.
• Evaluation of anti-inflammatory and antioxidant effects in experimental models.

Main Results:

• Doxycycline demonstrated capacity to disrupt or inhibit prion protein aggregate formation.
• Positive results were observed in treating peripheral amyloidosis.
• Doxycycline interacts with beta-amyloid, alpha-synuclein oligomers, and tau aggregation.
• Anti-inflammatory and antioxidant effects were noted, potentially explaining efficacy in models of neuroinflammation.

Conclusions:

• Doxycycline exhibits pleiotropic actions, including anti-amyloidogenic, anti-prion, anti-inflammatory, and antioxidant effects.
• Its favorable safety profile supports long-term treatment, particularly for peripheral amyloidosis.
• Doxycycline represents a valuable tool for addressing neuronal dysfunction in multifactorial neurodegenerative diseases.
• Precision medicine approaches are crucial for optimizing doxycycline's therapeutic efficacy.